We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Anaptysbio Inc
3 own
3 watching
Current Price
$18.65
$0.01
(0.05%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
531.77M
52-Week High
32.435
52-Week Low
18.03
Average Volume
0.09M
Dividend Yield
--
P/E Ratio
121.2182
Market Capitalization531.77M52-Week High32.43552-Week Low18.03Average Volume0.09MDividend Yield--P/E Ratio121.2182What does the Anaptysbio Inc do?
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Read More
How much money does Anaptysbio Inc make?
News & Events about Anaptysbio Inc.
Globe Newswire
27days ago
Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4Flare control sustained on monthly subcutaneous doses through Week 16Imsidolimab was generally safe and well tolerated with low overall ADA incidenceTop-line GEMINI-1 Phase 3 trial...
Ticker Report
2 months ago
AnaptysBio, Inc. (NASDAQ:ANAB Get Rating) Wedbush issued their Q1 2024 earnings estimates for shares of AnaptysBio in a report released on Thursday, March 2nd. Wedbush analyst D. Nierengarten expects that the biotechnology company will earn ($1.11) per share for the quarter. The ...
Globe Newswire
4 months ago
SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up ...
Globe Newswire
5 months ago
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer First-in-class pivotal data in endometrial cancer, if approved, to be a potential significant driver of...
Globe Newswire
7 months ago
Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancerCOSTAR, a Phase 2 trial of JEMPERLI plus cobolimab, an anti-TIM-3 antagonist antibody licensed to TESARO, Inc. (GSK) as part of the same ...
Frequently Asked Questions
Frequently Asked Questions
What is Anaptysbio Inc share price today?
Can Indians buy Anaptysbio Inc shares?
How can I buy Anaptysbio Inc shares from India?
Can Fractional shares of Anaptysbio Inc be purchased?
What are the documents required to start investing in Anaptysbio Inc stocks?
What is today’s traded volume of Anaptysbio Inc?
What is today’s market capitalisation of Anaptysbio Inc?
What is the 52-Week High and Low Range of Anaptysbio Inc?
What percentage is Anaptysbio Inc down from its 52-Week High?
What percentage is Anaptysbio Inc up from its 52-Week Low?
Current Price
$18.65
$0.01
(0.05%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.